Pharmacogenetics investigates the influence of genetic variants on physiological
phenotypes related to drug response and disease, while pharmacogenomics takes a …

Numerous genes encode G protein-coupled receptors (GPCRs)-a main molecular target for
drug therapy. Estimates indicate that the human genome contains approximately 600 GPCR …

Common G protein-coupled receptor (GPCR) gene variants that encode receptor proteins
with a distinct sequence may alter drug efficacy without always resulting in a disease …

Introduction: Guanine nucleotide binding proteins (G-proteins) represent the targets for>
50% of all therapeutics. There is substantial interindividual variation in response to agonists …

G protein-coupled receptors (GPCRs) represent a major class of proteins in the genome of
many species, including humans. In addition to the mapping of a number of human …

Genetic variation in G protein-coupled receptors (GPCRs) results in the disruption of GPCR
function in a wide variety of human genetic diseases. In vitro strategies have been used to …

G-protein-coupled receptors (GPCRs), including 'orphan'GPCRs whose natural ligands are
unknown, comprise the largest membrane receptor superfamily and are the most commonly …

The superfamily of G-protein–coupled receptors (GPCRs) is one of the largest and most
studied families of proteins. We created Hidden Markov Models derived from sorted groups …

G protein–coupled receptors (GPCRs) respond to a chemically diverse plethora of signal
transduction molecules. The notion that GPCRs also signal without an external chemical …

Polymorphisms of G-protein coupled receptor (GPCR) genes are associated with disease
risk and modification, and the response to receptor-directed therapy. Genomic sequencing …